At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 227 enrolled
Drug / intervention
paricalcitol +1 moredrug
Likely dose
paricalcitol 2 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The PRIMO Study: Paricalcitol Capsules Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4
In Brief
A Phase 3 clinical trial evaluating paricalcitol and placebo for Chronic Kidney Disease and Left Ventricular Hypertrophy. Completed, enrolled 227 participants across 71 sites in 12 countries.
Detailed Summary
To evaluate the effects of paricalcitol capsules on cardiac structure and function over 48 weeks in patients with Stage 3/4 chronic kidney disease (CKD) who had left ventricular hypertrophy (LVH).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Czechia, Germany, Italy, Poland, Puerto Rico, Romania, Russia, Spain, Taiwan, United Kingdom, United States
CollaboratorsMassachusetts General Hospital
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2007
Enrollment StartFeb 2008
Primary CompletionSep 2010
Study CompletionMar 2012
TodayJul 2026
First PostedJul 6, 2007
Enrollment StartFeb 1, 2008
Primary CompletionSep 1, 2010
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 19.0 years ago
Interventions
paricalcitoldrug
2 µg capsule
placebodrug
placebo capsule